{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:09Z","timestamp":1761518889950,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.3816\/cbc.2005.n.019","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:36Z","timestamp":1221080856000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Final Results of a Phase II Trial of Preoperative TAC (Docetaxel\/Doxorubicin\/Cyclophosphamide) in Stage III Breast Cancer"],"prefix":"10.3816","volume":"6","author":[{"given":"Ruth M.","family":"O'Regan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie H.","family":"Von Roenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ummekalsoom","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Staradub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borko","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2005.n.019_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.10741","article-title":"Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CBC.2005.n.019_bib2","first-page":"96","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"30","author":"Wolmark","year":"1999","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.3816\/CBC.2005.n.019_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer significantly enhanced response with docetaxel","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2005.n.019_bib4","first-page":"S9","article-title":"Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial","volume":"82","author":"Hutcheon","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2005.n.019_bib5","first-page":"210","article-title":"The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results of the NSABP protocol B-27","volume":"69","author":"NSABP","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2005.n.019_bib6","first-page":"43a","article-title":"Dose-dense versus sequential Adriamycin\/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0): primary endpoint analysis of the GEPARDUO study","volume":"21","author":"von Minckwitz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib7","first-page":"34a","article-title":"Dose-dense sequential epirubicin- paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study","volume":"21","author":"Untch","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib8","first-page":"36a","article-title":"Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study","volume":"21","author":"Nabholtz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib9","unstructured":"Martin M, Pienkowski T, Mackey J, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001:55 month follow-up. Presented at the 26th Annual San Antonio Breast Cancer Symposium; December 2003; San Antonio, TX (Abstract #43)."},{"key":"10.3816\/CBC.2005.n.019_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.3816\/CBC.2005.n.019_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CBC.2005.n.019_bib13","first-page":"35a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2005.n.019_bib14","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CBC.2001.s.002","article-title":"The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies","volume":"2","author":"Nabholtz","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2005.n.019_bib15","first-page":"36","article-title":"Neoadjuvant docetaxel followed by adjuvant doxorubicin and cytoxan for stage III breast cancer: clinical response and long-term survival","volume":"22","author":"Swain","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib16","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2003.01.136","article-title":"International Expert Panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations","volume":"21","author":"Kaufmann","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.n.019_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","article-title":"Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer","volume":"362","author":"Chang","year":"2003","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:18Z","timestamp":1761513018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911707157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1526820911707157"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2005.n.019","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Results of a Phase II Trial of Preoperative TAC (Docetaxel\/Doxorubicin\/Cyclophosphamide) in Stage III Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2005.n.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}